Form 4: IOVANCE CEO Vogt's RSU Vesting and Tax Withholding

IOVANCE BIOTHERAPEUTICS' Interim CEO & General Counsel, Frederick G. Vogt, reported the vesting of 62,493 Restricted Stock Units and subsequent tax withholding.

Summary

• Frederick G. Vogt, Interim CEO & General Counsel of IOVANCE BIOTHERAPEUTICS, INC., reported changes in his beneficial ownership.
• On March 5, 2026, 62,493 Restricted Stock Units (RSUs) vested, converting into an equal number of common stock shares.
• To satisfy mandatory tax withholding requirements, 26,755 shares were withheld by the Issuer at a price of $4.58 per share.
• Following these transactions, Vogt's direct beneficial ownership of common stock is 529,538 shares.
• He retains 125,007 unvested RSUs from a grant made on March 5, 2025, which are scheduled to vest in equal quarterly installments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and a modest increase in direct beneficial ownership, without indicating any new strategic developments or financial performance issues.

Positives

• Vesting of 62,493 Restricted Stock Units indicates a milestone achieved in the executive's compensation plan.
• The executive's beneficial ownership of common stock increased by 35,738 shares (62,493 acquired minus 26,755 withheld for taxes).

Negatives

• A significant portion of vested shares (26,755 shares) was withheld for tax purposes, reducing the net shares received by the executive.

Future Outlook

The filing indicates that the remaining 125,007 RSUs will vest in equal quarterly installments, suggesting continued long-term incentive alignment.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard practices in executive compensation across the biotechnology and pharmaceutical industries. This transaction reflects a routine compensation event rather than a strategic shift or market-moving development.

Comparison to Industry Standards

• RSU vesting and tax withholding at market price are standard compensation mechanisms. For example, executives at companies like Amgen or Gilead Sciences frequently report similar Form 4 transactions as their equity awards vest, aligning executive incentives with shareholder value over time.
• The withholding price of $4.58 per share reflects the market value at the time of the tax event.

Related Party Transactions

• The transaction involves an executive and the company, which is a related party transaction in the context of compensation, but it is a standard, disclosed compensation event.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not directly impact the company's operational performance or financial health. It slightly increases the executive's alignment with shareholder interests through increased direct ownership.
• Employees: No direct impact on employees beyond the executive.

Next Steps

• The remaining 125,007 RSUs granted on March 5, 2025, are scheduled to vest in equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving RSU vesting and tax withholding. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The increase in the executive's direct beneficial ownership is a minor positive for alignment but is not a catalyst for a 'buy' or 'sell' decision. Therefore, a 'hold' recommendation is appropriate as investors should look to other filings for more substantive company updates.

Keywords

IOVANCE BIOTHERAPEUTICS, IOVA, Frederick G. Vogt, SEC Form 4, Restricted Stock Units, RSU vesting, Insider Trading, Executive Compensation, Stock Ownership, Tax Withholding